| Repligen's Q4 Earnings Beat Estimates, Revenues In Line |
RGEN reports decent fourth-quarter results and issues guidance for 2025. |
zacks.com |
2025-02-21 13:35:30 |
Czytaj oryginał (ang.) |
| Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript |
Repligen Corporation (NASDAQ:RGEN ) Q4 2024 Earnings Call Transcript February 20, 2025 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Matt Hewitt - Craig Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen. |
seekingalpha.com |
2025-02-20 16:53:12 |
Czytaj oryginał (ang.) |
| Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook |
Repligen Corp RGEN released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents. |
benzinga.com |
2025-02-20 16:00:57 |
Czytaj oryginał (ang.) |
| Repligen's Q4 Slightly Tops Expectations |
Repligen (RGEN 7.92%), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus estimate of $0.41, but fell year over year. |
fool.com |
2025-02-20 13:25:28 |
Czytaj oryginał (ang.) |
| Repligen (RGEN) Beats Q4 Earnings Estimates |
Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago. |
zacks.com |
2025-02-20 11:45:22 |
Czytaj oryginał (ang.) |
| Repligen to Report Fourth Quarter and Full Year 2024 Financial Results |
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET |
globenewswire.com |
2025-02-11 09:30:00 |
Czytaj oryginał (ang.) |
| HRMY vs. RGEN: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-01-30 14:41:12 |
Czytaj oryginał (ang.) |
| Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains? |
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-01-29 06:20:12 |
Czytaj oryginał (ang.) |
| Repligen price target lowered to $180 from $240 at H.C. Wainwright |
H.C. Wainwright lowered the firm's price target on Repligen to $180 from $240 and keeps a Buy rating on the shares. The firm says the company could generate solid top- and bottom-line growth in the coming year. It lowered the price target saying Repligen's "explosive growth" of the COVID-19 years is no longer evident, but notes that the company's risk profile and overall positioning remain attractive. |
https://thefly.com |
2025-01-23 08:06:48 |
Czytaj oryginał (ang.) |
| HRMY or RGEN: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-01-14 14:40:19 |
Czytaj oryginał (ang.) |
| Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference |
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. |
globenewswire.com |
2025-01-07 09:30:00 |
Czytaj oryginał (ang.) |
| Repligen Launches the CTech™ SoloVPE® PLUS System |
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. |
globenewswire.com |
2025-01-06 09:30:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions Appoints Tony J. Hunt to its Board of Directors |
BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. |
prnewswire.com |
2024-12-16 10:11:00 |
Czytaj oryginał (ang.) |
| Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue? |
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:22 |
Czytaj oryginał (ang.) |
| Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report |
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “Advancing Impacts”, this newly reformatted report streamlines the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2023 Sustainability Report are detailed disclosures aligned with four key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs) and Task Force on Climate-Related Disclosures (TCFD). |
globenewswire.com |
2024-12-12 09:30:00 |
Czytaj oryginał (ang.) |
| Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns |
Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines |
globenewswire.com |
2024-12-09 09:30:00 |
Czytaj oryginał (ang.) |
| Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript |
Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Evan Stock - Wells Fargo Matthew Hewitt - Craig-Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Matt Stanton - Jefferies LLC Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Third Quarter of 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-12 17:07:27 |
Czytaj oryginał (ang.) |
| Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View |
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS. |
zacks.com |
2024-11-12 16:40:33 |
Czytaj oryginał (ang.) |
| Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth |
Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. |
benzinga.com |
2024-11-12 15:19:20 |
Czytaj oryginał (ang.) |
| Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates |
Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago. |
zacks.com |
2024-11-12 12:05:23 |
Czytaj oryginał (ang.) |
| Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects |
Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty. |
seekingalpha.com |
2024-11-12 08:36:27 |
Czytaj oryginał (ang.) |
| Repligen Corporation to Present at Upcoming Investor Conferences |
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. |
globenewswire.com |
2024-11-05 09:30:00 |
Czytaj oryginał (ang.) |
| Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release |
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-22 15:05:49 |
Czytaj oryginał (ang.) |
| Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More |
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics was estimated at US$42.1 Billion in 2023 and is projected to reach US$56.2 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, which are naturally occurring biological molecules, serve as signaling agents in the body and have high specificity for their targets, making them attractive candidates for therapeutic development. Innovations in peptide engineering have led to the development of modified peptides that resist enzymatic degradation, improve bioavailability, and have extended half-lives, allowing for less frequent dosing. |
globenewswire.com |
2024-10-14 15:15:00 |
Czytaj oryginał (ang.) |
| Repligen Opens Training & Innovation Center to Elevate Customer Experience |
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters. |
globenewswire.com |
2024-09-24 11:30:00 |
Czytaj oryginał (ang.) |
| Repligen Corporation to Present at Wells Fargo Healthcare Conference |
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. |
globenewswire.com |
2024-08-23 11:30:00 |
Czytaj oryginał (ang.) |
| Exclusive: Repligen in bid for reagent vendor Maravai, sources say |
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday. |
reuters.com |
2024-08-16 15:46:16 |
Czytaj oryginał (ang.) |
| Here's Why Shares in This Hot Healthcare Stock Surged This Week |
A far larger peer backs up Repligen's market commentary. Bioprocessing customers are working through inventory, and orders growth is bouncing back. |
fool.com |
2024-08-02 11:09:48 |
Czytaj oryginał (ang.) |
| These Analysts Revise Their Forecasts On Repligen Following Q2 Results |
Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday. |
benzinga.com |
2024-07-31 18:50:50 |
Czytaj oryginał (ang.) |
| Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates |
Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. |
zacks.com |
2024-07-31 15:51:16 |
Czytaj oryginał (ang.) |
| Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript |
Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Tony Hunt - CEO Jason Garland - CFO Olivier Loeillot - President & CCO Sondra Newman - IR Conference Call Participants Rachel Vatnsdal - J.P. Morgan Dan Arias - Stifel Jacob Johnson - Stephens Inc. Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Matt Larew - William Blair Conor McNamara - RBC Capital Markets Dan Leonard - UBS Paul Knight - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Matt Stanton - Jefferies Tom DeBourcy - Nephron Research Subbu Nambi - Guggenheim Securities Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Second Quarter of 2024 Earnings Conference Call. |
seekingalpha.com |
2024-07-30 19:03:09 |
Czytaj oryginał (ang.) |
| Repligen Lowers Guidance On China Weakness, Analyst Expects |
Tuesday, Repligen Corporation RGEN reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million. |
benzinga.com |
2024-07-30 16:01:42 |
Czytaj oryginał (ang.) |